Skip to main content

Neumora Therapeutics, Inc.

NMRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001885522

In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Neumora Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of NMRA: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders9893−5
Shares56.0M50.7M−5.35M (−9.5%)
Value$41.1M$92.2M+$51.1M (+124.3%)

New holders (13)

Institutions that held Neumora Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to NMRA in Q3 2025
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc830,818$1.51M0.01%
Ameriprise Financial Inc117,504$213.9K0.00%
Meridian Wealth Management, LLC59,400$108.1K0.00%
Jefferies Financial Group Inc.46,600$84.8K0.00%
Susquehanna Portfolio Strategies, LLC41,240$75.1K0.00%
Point72 Asia (Singapore) Pte. Ltd.31,444$57.2K0.01%
Public Employees Retirement System of Ohio24,300$44.2K0.00%
Brookstone Capital Management23,201$42.2K0.00%
Virtu Financial LLC17,219$31.0K0.00%
Legacy Private Trust Co.14,000$25.5K0.00%
SRS Capital Advisors, Inc.12,445$22.6K0.00%
Simplex Trading, LLC8,501$15.0K0.00%
Fortitude Family Office, LLC1,022$1.86K0.00%

Sold out (18)

Institutions that held Neumora Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.